Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
IGR-M5253 | Mouse | Mouse IGF-I R / CD221 Protein, Fc Tag |
|
||
CNIH-ATP102 | Human | NIH-3T3/Human IGF-1 R Stable Cell Line Development Service | |||
IGR-H5253 | Human | Human IGF-I R / CD221 Protein, Fc Tag |
|
||
IGR-H82E3 | Human | Biotinylated Human IGF-I R / CD221 Protein, His,Avitag™ |
|
||
IGR-H5229 | Human | Human IGF-I R / CD221 Protein, His Tag (MALS verified) |
|
||
IGR-C5225 | Cynomolgus | Cynomolgus IGF-I R / CD221 Protein, His Tag (MALS verified) |
|
||
IGR-R5224 | Rat | Rat IGF-I R / CD221 Protein, His Tag (MALS verified) |
|
||
IGR-M5223 | Mouse | Mouse IGF-I R / CD221 Protein, His Tag |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Dwarfism; Diabetes Mellitus, Lipoatrophic | null | 1994-10-05 | HIV Infections; Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; Lipodystrophy; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | IGF-1; FK-780; MKN-031 | Approved | Ipsen | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; X-Linked Combined Immunodeficiency Diseases; Phelan-McDermid syndrome; Growth Disorders; Muscular Dystrophy, Duchenne; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic | Details |
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Colorectal Neoplasms; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms; Glioblastoma; Stomach Neoplasms | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001 | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Sarcoma; Breast Neoplasms; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Dwarfism; Diabetes Mellitus, Lipoatrophic | null | 1994-10-05 | HIV Infections; Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; Lipodystrophy; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | IGF-1; FK-780; MKN-031 | Approved | Ipsen | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; X-Linked Combined Immunodeficiency Diseases; Phelan-McDermid syndrome; Growth Disorders; Muscular Dystrophy, Duchenne; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic | Details |
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Colorectal Neoplasms; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms; Glioblastoma; Stomach Neoplasms | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001 | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Sarcoma; Breast Neoplasms; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Veligrotug | ZB-001; VRDN-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
Teprotumumab biosimilar(Innovent) | IBI-311 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Graves Ophthalmopathy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma | Details |
Conteltinib | CT-707; SY-707 | Phase 3 Clinical | Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
lonigutamab ugodotin | W-0101 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours | Details |
Mecasermin Rinfabate | OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome | Details |
MHB018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details | |
Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Burns; Sunburn | Details | |
SAR-446159 | ABL-301; SAR-446159 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
VRDN-003 | VRDN-003 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms | Details |
ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Teprotumumab(Zhejiang Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
PHP-1003 | PHP-1003; PHP1003 | Phase 1 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
Veligrotug | ZB-001; VRDN-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
Teprotumumab biosimilar(Innovent) | IBI-311 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Graves Ophthalmopathy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma | Details |
Conteltinib | CT-707; SY-707 | Phase 3 Clinical | Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
lonigutamab ugodotin | W-0101 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours | Details |
Mecasermin Rinfabate | OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome | Details |
MHB018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details | |
Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Burns; Sunburn | Details | |
SAR-446159 | ABL-301; SAR-446159 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
VRDN-003 | VRDN-003 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms | Details |
ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Teprotumumab(Zhejiang Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
PHP-1003 | PHP-1003; PHP1003 | Phase 1 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
This web search service is supported by Google Inc.